EP 4037690 A1 20220810 - COMBINED THERAPY COMPRISING AN INHIBITOR OF INTERLEUKIN-17 ACTIVITY AND A VITAMIN D RECEPTOR AGONIST
Title (en)
COMBINED THERAPY COMPRISING AN INHIBITOR OF INTERLEUKIN-17 ACTIVITY AND A VITAMIN D RECEPTOR AGONIST
Title (de)
KOMBINATIONSTHERAPIE MIT EINEM HEMMER DER INTERLEUKIN-17-AKTIVITÄT UND EINEM VITAMIN-D-REZEPTORAGONISTEN
Title (fr)
POLYTHÉRAPIE COMPRENANT UN INHIBITEUR DE L'ACTIVITÉ DE L'INTERLEUKINE-17 ET UN AGONISTE DU RÉCEPTEUR DE LA VITAMINE D
Publication
Application
Priority
- EP 19382836 A 20190930
- EP 2020077227 W 20200929
Abstract (en)
[origin: EP3797779A1] The invention relates to a combined therapy including an inhibitor of interleukin-17 (IL-17) activity for use in combination with a vitamin D receptor agonist in the prevention and/or treatment of diseases or conditions known as autoimmune and autoinflammatory concomitant diseases, such as autoimmune kidney diseases, autoimmune joint diseases, skin autoimmune diseases, autoimmune neurological diseases, autoimmune thyroid diseases, and gout disease. The invention provides also the combination for use in the treatment and/or prevention of cancer, in which deregulation of immune system takes place. The invention also relates to the therapeutic combination and to its use in the treatment or prevention of proteinuria.
IPC 8 full level
A61K 31/59 (2006.01); A61K 39/00 (2006.01); A61P 13/12 (2006.01)
CPC (source: EP)
A61K 31/592 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 13/12 (2018.01); C07K 16/244 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01)
C-Set (source: EP)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
EP 3797779 A1 20210331; EP 4037690 A1 20220810; WO 2021063945 A1 20210408
DOCDB simple family (application)
EP 19382836 A 20190930; EP 2020077227 W 20200929; EP 20785714 A 20200929